Core Viewpoint - The article emphasizes the transition of AI in healthcare from a focus on large model parameters to practical applications that solve real-world problems, particularly in the medical payment sector [2][3][4]. Industry Trends - The World Artificial Intelligence Conference (WAIC) highlighted "AI + Healthcare" as a central theme, indicating that the industry is moving towards integrating AI into real medical scenarios rather than merely competing on model performance [2][3]. - The healthcare system faces a structural dilemma known as the "medical impossible triangle," where high-quality service, broad coverage, and low costs are difficult to achieve simultaneously. AI and big data are seen as potential solutions to break this triangle and enhance healthcare accessibility [2]. Company Insights - Megxin Health, a multi-payment platform based in Shanghai, is leveraging AI to reconstruct the medical payment ecosystem, aiming to integrate the value chain of medicine, pharmaceuticals, and insurance [2][8]. - As of June 30, Megxin Health reported serving over 1.6 million patients with a total medical payment amount (GPV) of 39.7 billion yuan, collaborating with over 90 insurance companies and more than 140 pharmaceutical companies, including 90 of the top 20 global pharmaceutical firms [8]. AI Integration and Development - The article discusses the evolution of AI in healthcare from single-point breakthroughs to system integration, with a focus on creating a commercial closed loop rather than just improving algorithm performance [5][6]. - Megxin Health's AI central platform, named "mind42.ai," is designed to facilitate the integration of medical, pharmaceutical, and insurance sectors, enhancing decision-making efficiency and automating core processes [9][11]. Challenges and Solutions - The medical payment landscape is complex, requiring high precision in decision-making due to the financial implications for patients and insurance companies. AI's role is to enhance this precision through collaborative efforts of multiple AI agents [13][14]. - The article highlights the need for AI to understand medical logic and insurance calculations, which traditional methods struggle to achieve. Megxin Health's AI agent cluster aims to address this by creating a collaborative network for efficient task completion [14][16]. Future Prospects - The future of AI in healthcare payment is expected to evolve towards intelligent risk management and actuarial-driven processes, reshaping the logic of risk pricing in health insurance [19]. - Megxin Health is committed to ensuring the fairness and transparency of AI decision-making processes, addressing concerns about algorithmic bias and data privacy [20]. Conclusion - The essence of medical payment should be to safeguard patients' dignity rather than create barriers. The success of AI in this domain will be measured not just by efficiency but by its ability to alleviate anxiety for families facing health challenges [21].

Financial Performance - In 2024, the company achieved total revenue of 36.726 billion CNY, a year-on-year increase of 5.14% [2] - The net profit attributable to shareholders was 11.668 billion CNY, up 0.74% year-on-year; excluding financial expenses, the net profit growth was 4.36% [2] - Operating cash flow reached 12.432 billion CNY, reflecting a year-on-year increase of 12.38% [2] - For Q1 2025, total revenue was 8.237 billion CNY, a decline of 12.12% compared to the same period last year, with net profit down 16.81% [9] Dividend Distribution - The company plans to distribute 679 million CNY (including tax) as dividends for 2024, with a cumulative cash dividend of 7.602 billion CNY, representing a payout ratio of 65.15% [3] - A proposal for a mid-year dividend of 1.71 billion CNY (including tax) for 2025 is also in place, pending shareholder approval [3] Market Performance International Market - The international market grew by 21.28% in 2024, with the Asia-Pacific region seeing nearly 40% growth driven by countries like Australia, Thailand, and India [4] - International revenue accounted for approximately 45% of total revenue, with high-potential segments like minimally invasive surgery and cardiovascular care nearing 10% of international income [4] Domestic Market - The domestic market experienced a decline of 5.10% due to sluggish hospital equipment procurement and the impact of DRG 2.0 [4] - A recovery is anticipated in Q3 2025 as local fiscal pressures ease and medical equipment projects are initiated [4] Product Line Performance In Vitro Diagnostics (IVD) - The IVD segment grew by 10.82% in 2024, with international IVD growth exceeding 30% [5] - IVD revenue now constitutes 37.48% of total company revenue, surpassing the life information and support segment [5] Medical Imaging - The medical imaging segment grew by 6.60%, with international growth over 15% [7] - The launch of the high-end Resona A20 ultrasound is expected to enhance market presence [7] Life Information and Support - This segment saw a decline of 11.11%, although international growth was in double digits [8] - The company maintains a leading market share in domestic monitoring and respiratory devices despite challenges [8] Research and Development - R&D investment for 2024 was 4.008 billion CNY, accounting for 10.91% of revenue, while Q1 2025 saw 847 million CNY in R&D, representing 10.28% of revenue [11] - New product launches include advanced systems in life information and support, IVD, and medical imaging [12][13] Sustainability Efforts - The company received an AA rating from MSCI ESG and was included in the S&P Global Sustainable Development Yearbook [14] - Carbon emissions intensity decreased by 11.6% compared to 2021, with ongoing projects contributing to sustainability goals [15] Future Outlook - The company anticipates a significant recovery in domestic revenue starting Q3 2025, driven by the resumption of medical equipment projects [10] - Long-term growth strategies focus on digitalization, internationalization, and enhancing the supply chain to adapt to changing market conditions [24][25]